Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Plus Decitabine in Elderly/Unfit Newly Diagnosed AML
NCT07117422Recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of venetoclax and decitabine in acute myeloid leukemia (AML), sponsored by The Second Hospital of Hebei Medical University. Primary endpoint: Complete Remission Rate at 42 days. Started Jan 2025; status: recruiting.
02
Drugs
venetoclaxdecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07117422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117422.